文献速递白血病MDS 与骨髓增殖性肿瘤

JAK2/p53突变巨核细胞/红系祖细胞中BMP2/SMAD通路激活促进白血病转化

BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation.
PubMed 文献 · Blood · 2022-01-01

该研究利用Jak2/Trp53突变骨髓增殖性肿瘤小鼠模型等位基因系列,发现仅Trp53双等位基因失活导致向纯红白血病转化,该过程源于巨核细胞-红系祖细胞群,BMP2/SMAD通路异常激活导致其异常自我更新,且转化细胞对WEE1与PARP联合抑制高度敏感。

要点

  • 仅Trp53双等位基因失活导致Jak2/Trp53突变骨髓增殖性肿瘤向纯红白血病转化。
  • 纯红白血病起源于巨核细胞-红系祖细胞群,BMP2/SMAD通路异常激活导致其异常自我更新。
  • 靶向活跃DNA修复通路,WEE1与PARP联合抑制对纯红白血病高度敏感。

核心结论

  • 仅Trp53双等位基因失活导致Jak2/Trp53突变骨髓增殖性肿瘤向纯红白血病转化。
  • BMP2/SMAD通路在白血病转化过程中异常激活并导致巨核细胞-红系祖细胞异常自我更新。
  • Jak2/Trp53突变纯红白血病以复发性拷贝数改变和DNA损伤为特征,对WEE1与PARP联合抑制高度敏感。

研究设计与样本

  • 研究使用Jak2/Trp53突变骨髓增殖性肿瘤小鼠模型的等位基因系列。

主要发现

  • 仅Trp53双等位基因失活导致向纯红白血病转化。
  • 纯红白血病起源于巨核细胞-红系祖细胞群。
  • BMP2/SMAD通路在白血病转化过程中异常激活并导致巨核细胞-红系祖细胞异常自我更新。
  • Jak2/Trp53突变纯红白血病以复发性拷贝数改变和DNA损伤为特征。
  • 靶向活跃DNA修复通路,纯红白血病对WEE1与poly(ADP-ribose) polymerase联合抑制高度敏感。

临床怎么用

  • 作者认为这些观察为p53突变白血病转化过程提供了新的机制见解,并提供了新的、可临床转化的治疗途径。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Leukemic transformation (LT) of myeloproliferative neoplasm (MPN) has a dismal prognosis and is largely fatal. Mutational inactivation of TP53 is the most common somatic event in LT; however, the mechanisms by which TP53 mutations promote LT remain unresolved. Using an allelic series of mouse models of Jak2/Trp53 mutant MPN, we identify that only biallelic inactivation of Trp53 results in LT (to a pure erythroleukemia [PEL]). This PEL arises from the megakaryocyte-erythroid progenitor population. Importantly, the bone morphogenetic protein 2/SMAD pathway is aberrantly activated during LT and results in abnormal self-renewal of megakaryocyte-erythroid progenitors. Finally, we identify that Jak2/Trp53 mutant PEL is characterized by recurrent copy number alterations and DNA damage. Using a synthetic lethality strategy, by targeting active DNA repair pathways, we show that this PEL is highly sensitive to combination WEE1 and poly(ADP-ribose) polymerase inhibition. These observations yield new mechanistic insights into the process of p53 mutant LT and offer new, clinically translatable therapeutic approaches.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Li B, An W, Wang H, et al. BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation. Blood. 2022. PMID: 35421216. doi:10.1182/blood.2021014465

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。